Skip to main content

Low-Dose Positron Emission Mammography Helps ID Breast Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 14, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 14, 2024 -- Low-dose positron emission mammography (PEM) is feasible for detecting invasive breast cancer, according to a study published online Feb. 9 in Radiology: Imaging Cancer.

Vivianne Freitas, M.D., from the University of Toronto, and colleagues examined the feasibility of low-dose PEM concurrent to magnetic resonance imaging (MRI) to identify breast cancer. Twenty-five female participants newly diagnosed with breast cancer underwent low-dose PEM with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose (18F-FDG). PEM images taken one and four hours following 18F-FDG injection were reviewed by two breast radiologists, unaware of the cancer location.

The researchers found that 24 of 25 cancers were identified with PEM from 100 sets of bilateral images; even after three hours of radiotracer uptake, performance was comparable. The median size of invasive cancer was 31 mm. At PEM, three additional in situ grade 2 lesions were missed. Compared with MRI, PEM detected fewer false-positive additional lesions, although the difference was not significant (16 versus 62 percent).

"While the full integration of this imaging method into clinical practice is yet to be confirmed, the preliminary findings of this research are promising, particularly in demonstrating the capability of detecting invasive breast cancer with low doses of fluorine-18-labeled FDG," Freitas said in a statement. "This marks a critical first step in its potential future implementation in clinical practice."

Several authors disclosed ties to Radialis Medical; one author holds a patent for organ-targeted solid-state tileable technology. Radialis Medical supplied equipment and assisted with maintenance.

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

Mortality in Rheumatic Heart Disease Is High

FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June...

Higher County-Level Prostate Cancer Screening Tied to Better Outcomes

FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...

Resistance Exercise Boosts Outcomes After Early-Stage Breast Cancer Surgery

FRIDAY, June 7, 2024 -- Early resistance exercise following surgery for early-stage breast cancer improves shoulder range of motion (ROM) and strength at one month and six months...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.